Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 13/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.74 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16048095 | 0.85 | AOC3 (1.00) | AOC3KCNH2 | |
| SCHEMBL19219061 | 0.84 | AOC3 (0.54) | AOC3KCNH2KDM4E | |
| SCHEMBL12091796 | 0.81 | APP (0.53) | AOC3KCNH2KDM4E | |
| SCHEMBL14983597 | 0.80 | AOC3 (0.51) | AOC3KCNH2 | |
| SCHEMBL14975632 | 0.77 | AOC3 (0.53) | AOC3KCNH2 | |
| SCHEMBL12091794 | 0.77 | AOC3 (0.52) | AOC3KCNH2 | |
| SCHEMBL9507245 | 0.77 | AOC3 (0.63) | AOC3KCNH2 | |
| SCHEMBL22997263 | 0.76 | AOC3 (0.55) | AOC3KCNH2 | |
| SCHEMBL16052854 | 0.76 | AOC3 (1.00) | AOC3KCNH2 | |
| SCHEMBL16053662 | 0.76 | AOC3 (1.00) | AOC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-20030139462-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2003-07-24 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020013354-A1 | p38 map kinase inhibitors | CHENG SOAN (US) | 2002-01-31 | — | — | US | disclosed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| CN-1279682-A | bicyclic kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2001-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013354-A1 | p38 map kinase inhibitors | MAPK1, MAPK8, MAP3K1 | AOC3 3969/4885KCNH2 4088/4885DYRK1A 3110/4885 |
| US-20030139462-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | AOC3 3969/4885KCNH2 4088/4885DYRK1A 3110/4885 |
| US-20010044538-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | AOC3 3969/4885KCNH2 4088/4885DYRK1A 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.